Skip to main content
Autobound logo

What Illumina's latest 10-Q says: 9 signals

Illumina filed its latest 10-Q with the SEC on Jul 31, 2026. It discusses acquisition completed, capex increase and compliance burden.

Public (ILMN)Biotechnology Research10,000+ employeesillumina.comLinkedIn

Filed
Jul 31, 2026
Filings
2
Signals
20

10-Q · latest 10

What Illumina's 10-Q filings say

  1. 10-Q

    Filed · 9 signals

    SEC EDGAR

  2. 10-Q

    Filed · 11 signals

    SEC EDGAR

Showing 10 of 20 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Illumina earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Launched 'BioInsight', a new business focused on AI and dataA new business unit, BioInsight, was created to combine population sequencing, data partnerships, and AI capabilities. This strategic investment in AI for drug discovery and research creates opportunities for vendors in data infrastructure, AI/ML platforms, and related services.
Launched new 'BioInsight' business unit for data, software, and AIA new business unit, BioInsight, has been created to consolidate population sequencing, data partnerships, software, and AI capabilities. This organizational change signals a strategic push to monetize data and AI-enabled services, likely triggering new budget allocation and vendor evaluations for data infrastructure, AI/ML platforms, and partnership management tools.
Launched multiple new products in multiomics and proteomicsThe company launched several new products, including 'Illumina Protein Prep' and a '5-base solution', expanding its portfolio into multiomics. New product launches require investment in marketing, sales enablement, and support systems, creating vendor opportunities.
Research market remains muted due to customer spending cautionThe research and applied end markets are a significant pain point, with sales declining due to customer funding uncertainty and careful spending. This challenge is expected to persist into 2026, making the company receptive to solutions that can help stimulate demand or improve sales efficiency in this difficult segment.
Actively working to close SomaLogic acquisition as key multiomics pillarThe pending acquisition of SomaLogic is a critical component of the company's strategic shift into multiomics. They are currently navigating the regulatory process, indicating active integration planning and investment in combining proteomics and genomics capabilities. This creates opportunities for M&A integration consultants and technology platform consolidation services.
Committed to multi-year growth and margin expansion targetsLeadership reiterated confidence in achieving high single-digit revenue growth and 20% non-GAAP operating margins by 2027. This long-term financial commitment underscores a strategic plan that will require sustained investment in growth initiatives and operational efficiency.

Signal API · MCP

Track Illumina with the Signal API

One POST /v1/companies/enrich call with illumina.com returns Illumina 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"illumina.com","signal_types":["sec-10q"],"limit":20}'

Same industry

10-Q at related companies

Questions about Illumina 10-Q

When did Illumina file its latest 10-Q?
Illumina filed its latest 10-Q on Jul 31, 2026. The one before it was filed on May 1, 2026.
What did Illumina disclose in its latest 10-Q?
From the filing dated Jul 31, 2026: Chief Strategy Officer Jakob Wedel adopted new 10b5-1 trading plan on May 19, 2026
What did Illumina say on its recent earnings calls?
Q3 FY2025: Launched 'BioInsight', a new business focused on AI and data (dated Oct 30, 2025).
Where can I read Illumina's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000160/ilmn-20260628.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →